inobrodib

inobrodib is a pioneering new drug that targets p300/CBP, to treat people with cancer.

[inobrodib @inobrodib]

CellCentric is headed to San Francisco for #JPM26! We look forward to connecting with the healthcare community and partners who share our vision for addressing unmet needs in #multiplemyeloma through novel, differentiated innovation. See you there!

[inobrodib @inobrodib]

As an all-oral regimen, InoPd has potential to enhance how #MM is managed in the community setting, where 70%+ of patients are treated. A well-tolerated and accessible treatment option, we believe InoPd could transform care for patients after, or instead of, BCMA/TCE agents.

[inobrodib @inobrodib]

New Phase 2 data at #ASH25 from our investigational, all-oral therapy InoPd (inobrodib + pom/dex) show promising clinical efficacy & tolerable safety profile in heavily pretreated patients with relapsed/refractory #MM. Initial positioning, after bispi. https://t.co/KSkWhFHDI9

[inobrodib @inobrodib]

Many #MM patients either are ineligible for a bispecific or cannot tolerate the treatment within the first few months. More to come @ #ASH25 from our Phase 2 expansion arm data of InoPd, with potential to address a major unmet need in the post-BCMA/TCE therapy patient population.

[inobrodib @inobrodib]

Many patients have no other options after relapsing on or not tolerating BCMA/TCE therapies; this is a significant new unmet need in long-term #MM care. With a novel MoA & all-oral regimen, InoPd can help reduce burden, support equity & give patients control. More @ #ASH25.

[inobrodib @inobrodib]

Looking forward to connecting in London to discuss the science & strategy behind inobrodib, our first-in-class oral p300/CBP inhibitor for #MM. Our near-term aim: offer an option for patients who relapsed on or weren’t eligible for TCE/BCMA therapies-a major & growing unmet need.

[inobrodib @inobrodib]

People with #MM often become resistant to IMiDs, a widely-used class of treatments that includes pom. Our investigational medicine inobrodib, has a synergistic mechanism with IMiDs such as pom, helping to re-sensitize tumors & potentially restore treatment response. More @ #ASH25

[inobrodib @inobrodib]

We’re excited to share that we will be presenting a poster on our novel investigational medicine inobrodib for the treatment of #multiplemyeloma at #ASH25 in December. Read the full release: https://t.co/l7eh0h39lD

[inobrodib @inobrodib]

We’re #hiring! Join our team as a Senior Clinical Supplies Manager and help us transform outcomes for people living with #multiplemyeloma. This is an initial 9 month contract with potential for extension. Learn more and apply today by emailing [email protected].

[inobrodib @inobrodib]

70%+ #MM patients are treated in a community setting. Accessibility matters. Community-based care extends reach, reduces disruption & eases burden on the healthcare system. InoPd, our all-oral regimen, has a novel MoA. Pivotal studies next year. Learn more https://t.co/IKLLbKyBfb

[inobrodib @inobrodib]

Bi-specifics have transformed #MM care.  Many patients ultimately relapse on these therapies, or cannot access, or are not eligible for them. InoPd, our all-oral regimen of inobrodib + pom+dex, is being developed to address this need & improve outcomes for people with MM.

[inobrodib @inobrodib]

Our all-oral InoPd (inobrodib + pom+dex) is moving into registration studies for relapsed/refractory #multiplemyeloma. It could improve community care with a truly novel mechanism and new treatment options. Learn more: https://t.co/2i3eNsFBc2

[inobrodib @inobrodib]

Despite advancements in #multiplemyeloma care, most people diagnosed still die from the condition. InoPd, our all-oral regimen of inobrodib combined with pom+dex, aims to address this unmet need. Clinical data expected later this year. Learn more: https://t.co/zCBVcjylF4

[inobrodib @inobrodib]

Experts aim to identify cancer signs years before symptoms emerge

https://t.co/iLxyZTjpbj

[inobrodib @inobrodib]

Initial clinical data, inobrodib treating relapsed refractory multiple myeloma, will be shared at ASH, next Saturday, New Orleans. Exciting times.

[inobrodib @inobrodib]

CellCentric presenting at #ASH22. Exciting Phase I data treating RR multiple myeloma, and other haems. Inobrodib: small molecule p300/CBP inhibitor. https://t.co/vUsMVyVlpN

[inobrodib @inobrodib]

CellCentric will be attending the International Myeloma Society-FDA joint meeting, 8-9 Nov. The future of multiple myeloma drug development.

[CellCentric @CellCentric]

CellCentric will be in Carlsbad, CA in Oct for the annual Prostate Cancer Foundation retreat. We continue to advance p300/CBP inhibition for the treatment of cancer.

[inobrodib @inobrodib]

Inobrodib’s development leadership is at ASCO. Pioneering the treatment of specific solid and haem cancers by inhibiting p300/CBP. @CellCentric #ASCO22

[inobrodib @inobrodib]

It’s international clinical trials day. Inobrodib is in Phase II to treat specific cancers in the UK, US and EU. Thank you patients, clinicians, clin ops team!